Skip to main content
Top
Published in: Indian Journal of Surgical Oncology 2/2024

15-12-2023 | Cystectomy | Original Article

Clinico-demographic Profile of Carcinoma Urinary Bladder—5-Year Experience from a Tertiary Care Centre of Eastern India

Authors: Koustav Biswas, Linkon Biswas, Soham Gangopadhyay, Arpan Jana, Tanmoy Basak, Debojyoti Manna, Srikrishna Mandal

Published in: Indian Journal of Surgical Oncology | Issue 2/2024

Login to get access

Abstract

Urinary bladder carcinoma is a disease of the elderly and often presents at an advanced stage due to ignorance and manifestation of symptoms at later stages of the disease. In India, very little data is available regarding the clinico-epidemiological pattern of urinary bladder cancers. In this study, we analysed the clinico-demographic profile of patients with urinary bladder carcinoma, attending a tertiary care centre in Eastern India over the last 5 years. We analysed the database of Oncology OPD of a tertiary care centre in West Bengal in Eastern India and collected the demographic, clinical and treatment data of urinary bladder carcinoma patients who attended our OPD between 2017 and 2021. The objective was to assess the demographic and clinical profile of these patients and compare them with those reported from other parts of India as well as the rest of the world. Majority of patients (70%) were above 50 years of age with a strikingly huge male predominance (male:female = 6.6:1). Transitional cell carcinoma (TCC) was the most common (90%) histology. 67.2% of the cases were muscle-invasive disease at presentation, and 19.3% of the patients presented with metastatic disease with bone (42%) as the most common site of metastasis. Overall, around 22% of patients underwent surgery either with definitive or palliative intent. Sixty-five percent of the patients who received radiotherapy underwent definitive radiation as a part of bladder preservation protocol. Thirty-five percent of all patients received chemotherapy; most of them (50.5%) received chemotherapy as neoadjuvant treatment before definitive therapy. To conclude, it can be said that this study is one of its first from Eastern India and will act as a stepping stone for future studies concentrating on clinico-epidemiological profile, early diagnosis and treatment of carcinoma urinary bladder.
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://​doi.​org/​10.​3322/​caac.​21660
2.
go back to reference van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ et al (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56(3):430–442CrossRefPubMed van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ et al (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56(3):430–442CrossRefPubMed
3.
go back to reference Gupta P, Jain M, Kapoor R, Muruganandham K, Srivastava A, Mandhani A (2009) Impact of age and gender on the clinicopathological characteristics of bladder cancer. Indian J Urol 25(2):207–210CrossRefPubMedPubMedCentral Gupta P, Jain M, Kapoor R, Muruganandham K, Srivastava A, Mandhani A (2009) Impact of age and gender on the clinicopathological characteristics of bladder cancer. Indian J Urol 25(2):207–210CrossRefPubMedPubMedCentral
4.
go back to reference Knowles MA (1999) The genetics of transitional cell carcinoma: progress and potential clinical application. BJU Int 84(4):412–427CrossRefPubMed Knowles MA (1999) The genetics of transitional cell carcinoma: progress and potential clinical application. BJU Int 84(4):412–427CrossRefPubMed
6.
go back to reference Ghagane S, Nerli R, Hiremath M, Wagh A, Magdum P (2016) Incidence of prostate cancer at a single tertiary care center in North Karnataka. Indian J Cancer 53:429–431CrossRefPubMed Ghagane S, Nerli R, Hiremath M, Wagh A, Magdum P (2016) Incidence of prostate cancer at a single tertiary care center in North Karnataka. Indian J Cancer 53:429–431CrossRefPubMed
7.
go back to reference Schatte E, Grunenfelder J, Fradet Y, Miles BJ (2000) Epidemiology of bladder cancer. In: Comprehensive textbook of genitourinary oncology, 2nd edition. Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, editors. Philadelphia: Lippincott, Williams and Wilkins, p. 283 Schatte E, Grunenfelder J, Fradet Y, Miles BJ (2000) Epidemiology of bladder cancer. In: Comprehensive textbook of genitourinary oncology, 2nd edition. Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, editors. Philadelphia: Lippincott, Williams and Wilkins, p. 283
12.
go back to reference (2006) The lower urinary tract. In: Kumar V, Abbas AK, Fausto N (eds) Robbins and Cotran Pathologic basis of disease, 7th edn. Saunders Co, Philadelphia, pp 1028–1032 (2006) The lower urinary tract. In: Kumar V, Abbas AK, Fausto N (eds) Robbins and Cotran Pathologic basis of disease, 7th edn. Saunders Co, Philadelphia, pp 1028–1032
13.
go back to reference (2000) The urinary bladder. In: Russell RCG, Williams NS, Bulstrode CJK (eds) Bailey and Love’s “Short practice of surgery,” 23rd edn. Arnold, London, pp 1227–1229 (2000) The urinary bladder. In: Russell RCG, Williams NS, Bulstrode CJK (eds) Bailey and Love’s “Short practice of surgery,” 23rd edn. Arnold, London, pp 1227–1229
14.
go back to reference Stadler WM (1993) Molecular events in the initiation and progression of bladder cancer. Int J Oncol 1993(3):549–557 Stadler WM (1993) Molecular events in the initiation and progression of bladder cancer. Int J Oncol 1993(3):549–557
15.
go back to reference Ahmed Z, Muzaffer S, Khan M, Kayani N, Pervez S, Husseini AS et al (2002) Transitional cell carcinomas of the urinary bladder. A histopathological study. J Pak Med Assoc 52(9):396–398 Ahmed Z, Muzaffer S, Khan M, Kayani N, Pervez S, Husseini AS et al (2002) Transitional cell carcinomas of the urinary bladder. A histopathological study. J Pak Med Assoc 52(9):396–398
16.
go back to reference Ullah R, Nusrat J, Hamdani SR, Burdy GM, Khurshid A (2001) Cancer urinary bladder-5 year experience at CENAR. Quetta J Ayub Med Coll Abottabad 13:14–16 Ullah R, Nusrat J, Hamdani SR, Burdy GM, Khurshid A (2001) Cancer urinary bladder-5 year experience at CENAR. Quetta J Ayub Med Coll Abottabad 13:14–16
17.
go back to reference Puranik SI, Ghagane SC, Nerli RB, Hiremath MB (2022) Incidence of bladder cancer at a tertiary care centre in north Karnataka. Middle East J Cancer 13(2):363–371 Puranik SI, Ghagane SC, Nerli RB, Hiremath MB (2022) Incidence of bladder cancer at a tertiary care centre in north Karnataka. Middle East J Cancer 13(2):363–371
19.
go back to reference Amonkar P, Murali G, Krishnamurthy S (2001) Schistosoma induced squamous cell carcinoma of the bladder. Indian J Pathol Microbiol 44:363–364PubMed Amonkar P, Murali G, Krishnamurthy S (2001) Schistosoma induced squamous cell carcinoma of the bladder. Indian J Pathol Microbiol 44:363–364PubMed
20.
go back to reference Bohle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90–95CrossRefPubMed Bohle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90–95CrossRefPubMed
22.
go back to reference Oddens J, Brausi M, Sylvester R et al (2013) Final results of an EORTCGU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 63(3):462–472. https://doi.org/10.1016/j.eururo.2012.10.039 Oddens J, Brausi M, Sylvester R et al (2013) Final results of an EORTCGU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 63(3):462–472. https://​doi.​org/​10.​1016/​j.​eururo.​2012.​10.​039
23.
24.
25.
go back to reference Sargos P, Baumann BC, Eapen L, Christodouleas J, Bahl A, Murthy V et al. (2018) Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy. Cancer Treat Rev 70:88–97. https://doi.org/10.1016/j.ctrv.2018.07.011 Sargos P, Baumann BC, Eapen L, Christodouleas J, Bahl A, Murthy V et al. (2018) Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy. Cancer Treat Rev 70:88–97. https://​doi.​org/​10.​1016/​j.​ctrv.​2018.​07.​011
26.
28.
go back to reference International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Group (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 29(16):2171–2177. https://doi.org/10.1200/JCO.2010.32.3139 International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Group (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 29(16):2171–2177. https://​doi.​org/​10.​1200/​JCO.​2010.​32.​3139
30.
go back to reference Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer; results of a large randomized multinational, multicentre phase III study. J Clin Oncol 18:3068–3077CrossRefPubMed Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer; results of a large randomized multinational, multicentre phase III study. J Clin Oncol 18:3068–3077CrossRefPubMed
Metadata
Title
Clinico-demographic Profile of Carcinoma Urinary Bladder—5-Year Experience from a Tertiary Care Centre of Eastern India
Authors
Koustav Biswas
Linkon Biswas
Soham Gangopadhyay
Arpan Jana
Tanmoy Basak
Debojyoti Manna
Srikrishna Mandal
Publication date
15-12-2023
Publisher
Springer India
Published in
Indian Journal of Surgical Oncology / Issue 2/2024
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-023-01861-2

Other articles of this Issue 2/2024

Indian Journal of Surgical Oncology 2/2024 Go to the issue